TPTX News and Press, Turning Point Therapeutics Inc. From 10/26/20

Turning Point Therapeutics (TPTX) has priced its public offering of 4,597,702 common shares at $87.00/share, for expected gross proceeds of ~$400M.Underwriters' over-allotment is an additional 689,655 shares.Closing date is October 29.Previously: Turning Point Therapeutics launches equity off...

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of 4,59...

Turning Point Therapeutics (TPTX) has commenced a public offering of $400M common shares.Underwriters' over-allotment is an additional 15% of the total offering.Press releasePreviously: Turning Point's TPX-0022 shows encouraging action in MET-driven cancers (Oct. 26) For further details see...

Preliminary Clinical Activity and Safety Profile Support Advanc ing to Dose Expansion in Multiple Tumor Types Recommended Phase 2 Dose Determination Ongoing Preclinical Combination Data for...

SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced it will host a conference call and webcast on Sat., Oct. 24 at 11:00 a.m. ET...

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that abstracts submitted for two of its drug candidates have been selected f...

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a qu...

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two ...